Interpreting Geographic Variations in Results of Randomized, Controlled Trials.

In large multinational clinical therapeutic trials, responses in one region can differ from those in another. This article examines reasons for such differences and suggests criteria for determining whether the differences are real or the play of chance.

[1]  S. Yusuf,et al.  Randomized Trial of Benznidazole for Chronic Chagas' Cardiomyopathy. , 2015, The New England journal of medicine.

[2]  Li-sheng Liu,et al.  Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial. , 2015, JAMA.

[3]  Akshay S. Desai,et al.  Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial , 2015, Circulation.

[4]  B. Greenwood,et al.  Efficacy and Safety of the RTS,S/AS01 Malaria Vaccine during 18 Months after Vaccination: A Phase 3 Randomized, Controlled Trial in Children and Young Infants at 11 African Sites , 2014, PLoS medicine.

[5]  Sanjiv J Shah,et al.  Spironolactone for heart failure with preserved ejection fraction. , 2014, The New England journal of medicine.

[6]  P. D. de Bakker,et al.  HLA-B*13:01 and the dapsone hypersensitivity syndrome. , 2013, The New England journal of medicine.

[7]  Z. Jing,et al.  Macitentan and morbidity and mortality in pulmonary arterial hypertension. , 2013, The New England journal of medicine.

[8]  S. Pocock,et al.  International differences in treatment effect: do they really exist and why? , 2013, European heart journal.

[9]  M. Khandelwal.  Vaginal progesterone in risk reduction of preterm birth in women with short cervix in the midtrimester of pregnancy , 2012, International journal of women's health.

[10]  Michael R. Johnson,et al.  HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. , 2011, The New England journal of medicine.

[11]  Chen-Yang Shen,et al.  Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. , 2011, The New England journal of medicine.

[12]  Horst Olschewski,et al.  Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. , 2010, Journal of the American College of Cardiology.

[13]  Claes Held,et al.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.

[14]  S. Yusuf,et al.  Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. , 2007, The New England journal of medicine.

[15]  S. Yusuf,et al.  Homocysteine lowering with folic acid and B vitamins in vascular disease. , 2006, The New England journal of medicine.

[16]  Salim Yusuf,et al.  Comparison of fondaparinux and enoxaparin in acute coronary syndromes. , 2006, The New England journal of medicine.

[17]  H Wedel,et al.  Challenges of subgroup analyses in multinational clinical trials: experiences from the MERIT-HF trial. , 2001, American heart journal.

[18]  Fach,et al.  Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.

[19]  R Peto,et al.  Why do we need some large, simple randomized trials? , 1984, Statistics in medicine.

[20]  Callaway Cw,et al.  Letter: Diabetic ketoacidosis. , 1974, Lancet.